JAK1 and congenital rubella syndrome: Since IL-17A signaling does not involve JAK-1/2 pathways, preserving the gut-protective IL-17A signaling pathways, and inhibiting only the pathogenic IFN-γ-driven JAK-1/2 pathways using JAK-1/2 inhibitors is likely a beneficial approach for treating CRS.